Đột biến gen EGFRvà mối liên quan với một số yếu tố lâm sàng ở bệnh nhân ung thư biểu mô tuyến phổi
Main Article Content
Abstract
The study was conducted to describe the characteristics of EGFR genetic mutation and its relationship with clinical features of lung adenocarcinoma patients. This prospective study analyzed data from 150 lung adenocarcinoma patients with inpatient treatment from January 2018 to August 2020 at Military Hospital 103 and National Cancer Hospital. Positive EGFR genetic mutation occurred in 39.3% of the participants, 86.44% had drug sensitivity mutation, exon 19 and exon 21 mutation rates are 50,8% and 35.6% respectively, and double mutation on both exons is 5.1%. EGFR genetic mutation took place more frequently in female and non - smoking patients. Symptoms such as dry cough, chest paint, shortness of breath or distant metastasis were not associated with having EGFR mutation. In conclusion, positive EGFR genetic mutation rate is 39.3% and EGRF genetic mutation relates to gender and smoking habit.
Article Details
Keywords
Lung Adenocarcinoma, Epidermal Growth Factor Receptor (EGFR).
References
2. Lynch, T.J., et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small - cell lung cancer to gefitinib. N Engl J Med, 2004. 350 (21): p. 2129 - 39.
3. Shi, Y., et al., A prospective, molecular epidemio logy study of EGFR mutations in Asian patients with advanced non - small - cell lung cancer of adenocarcinoma histo logy (PIONEER). J Thorac Oncol, 2014. 9 (2): p. 154 - 62.
4. Jackman, D.M., et al., Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non - small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res, 2009. 15 (16): p. 5267 - 73.
5. Nguyễn Thị Lan Anh., Nghiên cứu đặc điểm đột biến gen EGFR và mối liên quan với lâm sàng, cận lâm sàng ở bệnh nhân ung thư phổi biểu mô tuyến, in Nội hô hấp. 2017, Học Viện Quân Y
6. Chatterjee, K., A. Ray, and B. Chattopadhyay, Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non - small - cell lung cancer (Adenocarcinoma histo logy): A report of 106 patients from Kolkata. Indian J Cancer, 2017. 54 (1): p. 305 - 307.
7. Shigematsu, H. and A.F. Gazdar, Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer, 2006. 118 (2): p. 257 - 62.
8. Fukuoka, M., et al., Biomarker analyses and final overall survival results from a phase III, randomized, open - label, first - line study of gefitinib versus carboplatin/paclitaxel in 117 clinically selected patients with advanced non - small - cell lung cancer in Asia (IPASS). J Clin Oncol, 2011. 29 (21): p. 2866 - 74.
9.Vyse, S. and P.H. Huang, Targeting EGFR exon 20 insertion mutations in non - small cell lung cancer. Signal Transduct Target Ther, 2019. 4: p. 5.
10.Wei, Z., et al., Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non - small cell lung cancer when treated with EGFR - tyrosine kinase inhibitors. Thorac Cancer, 2014. 5 (2): p. 126 - 32.
11. Janne, P.A. and B.E. Johnson, Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res, 2006. 12 (14 Pt 2): p. 4416s - 4420s.
12. Jiang, H., et al., Association between EGFR exon 19 or exon 21 mutations and survival rates after first - line EGFR - thần kinhI treatment in patients with non - small cell lung cancer. Mol Clin Oncol, 2019. 11 (3): p. 301 - 308.
13. Girard, N., et al., Nomo gram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J, 2012. 39 (2): p. 366 - 72.
14. Zhang, P., et al., Impact of heavy smoking on the benefits from first - line EGFR - thần kinhI therapy in patients with advanced lung adenocarcinoma. Medicine (Baltimore), 2018. 97 (9): p. e0006.